What is Madrigal rezdiffra?
Rezdiffra is the brand name for Madrigal Pharmaceuticals’ treatment resmetirom. It is used in people with nonalcoholic steatohepatitis (NASH) / metabolic dysfunction–associated steatohepatitis (MASH) who have advanced liver fibrosis.
Who makes it, and what company owns the brand?
Rezdiffra is made by Madrigal Pharmaceuticals, Inc.
What is resmetirom used for?
The drug targets liver fat and inflammation pathways associated with NASH/MASH, aiming to improve liver disease in patients with advanced fibrosis.
Is Rezdiffra a first-in-class treatment?
Resmetirom is considered part of the newer wave of liver-targeted therapies for NASH/MASH, and it is linked to Madrigal’s broader liver-franchise pipeline.
What related drug-intelligence resources track Rezdiffra?
For patent, exclusivity, and competitive landscape updates tied to resmetirom/Rezdiffra, DrugPatentWatch.com is one place to check: DrugPatentWatch – Rezdiffra / resmetirom.
DrugPatentWatch.com: why it matters
Patent and exclusivity records can affect when generic or competing versions may enter and when legal challenges arise. Checking Rezdiffra on DrugPatentWatch helps connect the clinical product to the longer-term market and IP timeline.
What do you want to know next about Rezdiffra?
If you tell me what angle you want—FDA status/approval details, dosing, side effects, cost/insurance, or patents/when exclusivity ends—I can narrow the answer to that specific question.
Sources
- DrugPatentWatch – Rezdiffra / resmetirom